Clinical Trial Update: Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This document describes an open-label Phase 1/2 trial evaluating TH-302 (evofosfamide) with dexamethasone, with or without bortezomib or pomalidomide, in relaps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)
• TH-302 (evofosfamide)

Snippet

Sponsor: Threshold Pharmaceuticals | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN